ptx55u

Property	Value
?:abstract	Gender influences clinical presentations, duration and severity of symptoms, and therapy outcome in coronavirus disease 2019 (COVID-19) infection Whether the immune response to Talpha1 treatment for SARS-CoV-2 differs between the sexes, and whether this difference explains the male susceptibility to COVID-19, is unclear This study aimed to investigate the efficiency and safety of Talpha1 treatment and provide a basis for practically identifying gender differences characteristics and features of COVID-19 One hundred twenty-seven patients had COVID-19 symptoms and tested COVID19-positive (female 42 52%) in Wuhan union hospital were enrolled for medication They were randomly divided into groups Control and Talpha1 intervention Seventy-eight patients received a subcutaneous injection of 1 6 mg Talpha1, based on supportive treatment for 15 days The control group included untreated 49 COVID19 patients closely matched for gender and age and received regular supportive treatment In this retrospective analysis, we found that COVID-19-infected males reported more symptoms than COVID-19-infected females A high degree of gender differences-related variability was observed in CRP and PCT levels and the cell counts of many lymphocyte subpopulations in the COVID-19 patients after Talpha1 intervention Levels of CRP and IL-6 were higher in Talpha1-treated male group than Talpha1-treated female group, while the level of PCT was significantly lower in Talpha1-treated male group Gender differences may be a factor in sustaining COVID-19 immunity responded to Talpha1, male and female show statistically significant differences in relevance to cytokine production associated with the development of a more significant number of symptoms This leaves the question of identifying gender-specific risk factors to explain these differences Gender influences clinical presentations, duration and severity of symptoms, and therapy outcome in coronavirus disease 2019 (COVID-19) infection. Whether the immune response to Tα1 treatment for SARS-CoV-2 differs between the sexes, and whether this difference explains the male susceptibility to COVID-19, is unclear. This study aimed to investigate the efficiency and safety of Tα1 treatment and provide a basis for practically identifying gender differences characteristics and features of COVID-19. One hundred twenty-seven patients had COVID-19 symptoms and tested COVID19-positive (female 42.52%) in Wuhan union hospital were enrolled for medication. They were randomly divided into groups Control and Tα1 intervention. Seventy-eight patients received a subcutaneous injection of 1.6 mg Tα1, based on supportive treatment for 15 days. The control group included untreated 49 COVID19 patients closely matched for gender and age and received regular supportive treatment. In this retrospective analysis, we found that COVID-19-infected males reported more symptoms than COVID-19-infected females. A high degree of gender differences-related variability was observed in CRP and PCT levels and the cell counts of many lymphocyte subpopulations in the COVID-19 patients after Tα1 intervention. Levels of CRP and IL-6 were higher in Tα1-treated male group than Tα1-treated female group, while the level of PCT was significantly lower in Tα1-treated male group. Gender differences may be a factor in sustaining COVID-19 immunity responded to Tα1, male and female show statistically significant differences in relevance to cytokine production associated with the development of a more significant number of symptoms. This leaves the question of identifying gender-specific risk factors to explain these differences.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/38ptx55u_hasAnnotation_C0013227> <https://research.tib.eu/covid-19/entity/38ptx55u_hasAnnotation_C1457887> <https://research.tib.eu/covid-19/entity/38ptx55u_hasAnnotation_C1874451> <https://research.tib.eu/covid-19/entity/38ptx55u_hasAnnotation_C4305789> <https://research.tib.eu/covid-19/entity/38ptx55u_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Li%2C_X.%3B_Liu%2C_L.%3B_Yang%2C_Y.%3B_Yang%2C_X.%3B_Wang%2C_C.%3B_Li%2C_Y.%3B_Ge%2C_Y.%3B_Shi%2C_Y.%3B_Lv%2C_P.%3B_Zhou%2C_H.%3B_Luo%2C_P.%3B_Huang%2C_S.> <https://research.tib.eu/covid-19/entity/Li%2C_Xin%3B_Liu%2C_Lancong%3B_Yang%2C_Yi%3B_Yang%2C_Xuefeng%3B_Wang%2C_Cencen%3B_Li%2C_Yan%3B_Ge%2C_Yanyan%3B_Shi%2C_Yuxin%3B_Lv%2C_Ping%3B_Zhou%2C_Hua%3B_Luo%2C_Pei%3B_Huang%2C_Shilong>
?:journal	Int_Immunopharmacol International_Immunopharmacology
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:source	WHO
?:title	Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#1065208 #779057
?:year	2020 2021

Property

Value

?:abstract

Gender influences clinical presentations, duration and severity of symptoms, and therapy outcome in coronavirus disease 2019 (COVID-19) infection Whether the immune response to Talpha1 treatment for SARS-CoV-2 differs between the sexes, and whether this difference explains the male susceptibility to COVID-19, is unclear This study aimed to investigate the efficiency and safety of Talpha1 treatment and provide a basis for practically identifying gender differences characteristics and features of COVID-19 One hundred twenty-seven patients had COVID-19 symptoms and tested COVID19-positive (female 42 52%) in Wuhan union hospital were enrolled for medication They were randomly divided into groups Control and Talpha1 intervention Seventy-eight patients received a subcutaneous injection of 1 6 mg Talpha1, based on supportive treatment for 15 days The control group included untreated 49 COVID19 patients closely matched for gender and age and received regular supportive treatment In this retrospective analysis, we found that COVID-19-infected males reported more symptoms than COVID-19-infected females A high degree of gender differences-related variability was observed in CRP and PCT levels and the cell counts of many lymphocyte subpopulations in the COVID-19 patients after Talpha1 intervention Levels of CRP and IL-6 were higher in Talpha1-treated male group than Talpha1-treated female group, while the level of PCT was significantly lower in Talpha1-treated male group Gender differences may be a factor in sustaining COVID-19 immunity responded to Talpha1, male and female show statistically significant differences in relevance to cytokine production associated with the development of a more significant number of symptoms This leaves the question of identifying gender-specific risk factors to explain these differences
Gender influences clinical presentations, duration and severity of symptoms, and therapy outcome in coronavirus disease 2019 (COVID-19) infection. Whether the immune response to Tα1 treatment for SARS-CoV-2 differs between the sexes, and whether this difference explains the male susceptibility to COVID-19, is unclear. This study aimed to investigate the efficiency and safety of Tα1 treatment and provide a basis for practically identifying gender differences characteristics and features of COVID-19. One hundred twenty-seven patients had COVID-19 symptoms and tested COVID19-positive (female 42.52%) in Wuhan union hospital were enrolled for medication. They were randomly divided into groups Control and Tα1 intervention. Seventy-eight patients received a subcutaneous injection of 1.6 mg Tα1, based on supportive treatment for 15 days. The control group included untreated 49 COVID19 patients closely matched for gender and age and received regular supportive treatment. In this retrospective analysis, we found that COVID-19-infected males reported more symptoms than COVID-19-infected females. A high degree of gender differences-related variability was observed in CRP and PCT levels and the cell counts of many lymphocyte subpopulations in the COVID-19 patients after Tα1 intervention. Levels of CRP and IL-6 were higher in Tα1-treated male group than Tα1-treated female group, while the level of PCT was significantly lower in Tα1-treated male group. Gender differences may be a factor in sustaining COVID-19 immunity responded to Tα1, male and female show statistically significant differences in relevance to cytokine production associated with the development of a more significant number of symptoms. This leaves the question of identifying gender-specific risk factors to explain these differences.

is ?:annotates of